Press release
Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
* DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
* The leading Metastatic Castration-Resistant Prostate Cancer Companies working in the market include Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
* Promising Metastatic Castration-Resistant Prostate Cancer Therapies in the various stages of development include JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
* May 2024:- Janssen Research & Development LLC- A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer. The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).
* May 2024:- Bristol-Myers Squibb- A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer. The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
* May 2024:- Fusion Pharmaceuticals Inc.- A Phase 2/3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC), Previously Treated With 177Lu-PSMA Radioligand Therapy (RLT). The purpose of the dose optimization segment (Phase 2) is to determine the recommended FPI-2265 dose and regimen. Conclusions from Phase 2 will be based on safety, tolerability, and anti-tumor activity.
Request a sample and discover the recent advances in Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration-Resistant Prostate Cancer Overview
Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT).
Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named "hormone-refractory prostate cancer" and "androgen-independent prostate cancer". However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
* SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
* Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
* HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Find out more about Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Drugs for Metastatic Castration-Resistant Prostate Cancer Treatment [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment
There are approx. 75+ key Metastatic Castration-Resistant Prostate Cancer companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The Metastatic Castration-Resistant Prostate Cancer companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.
DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report covers around 75+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Learn more about the emerging Metastatic Castration-Resistant Prostate Cancer pipeline therapies @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Intravenous
* Subcutaneous
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Metastatic Castration-Resistant Prostate Cancer Companies
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
Dive deep into rich insights for new drugs for Metastatic Castration-Resistant Prostate Cancer Treatment, visit @ Metastatic Castration-Resistant Prostate Cancer Drugs [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
* Coverage- Global
* Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
* Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
For further information on the Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics, reach out @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic Castration Resistant Prostate cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Castration Resistant Prostate cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rucaparib: Clovis Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Surface Oncology: SRF 617
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* REGN 4336: Regeneron Pharamceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HP 518: Hinova Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Castration Resistant Prostate cancer Key Companies
* Metastatic Castration Resistant Prostate cancer Key Products
* Metastatic Castration Resistant Prostate cancer- Unmet Needs
* Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
* Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
* Metastatic Castration Resistant Prostate cancer Analyst Views
* Metastatic Castration Resistant Prostate cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-castrationresistant-prostate-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here
News-ID: 3491620 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
